

Journal of the Hellenic Veterinary Medical Society

Vol 73, No 2 (2022)



Field observation on the use of PRID®Delta to induce estrus and ovulation in anestrous mares

mounir mebarki, R Kaidi, M Basbaci

doi: [10.12681/jhvms.23127](https://doi.org/10.12681/jhvms.23127)

Copyright © 2022, mounir mebarki



This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0](https://creativecommons.org/licenses/by-nc/4.0/).

To cite this article:

mebarki, mounir, Kaidi, R., & Basbaci, M. (2022). Field observation on the use of PRID®Delta to induce estrus and ovulation in anestrous mares. *Journal of the Hellenic Veterinary Medical Society*, 73(2), 3935-3940.
<https://doi.org/10.12681/jhvms.23127>

Field observations on the use of Progestin device (PRID) for estrus and ovulation induction in anestrous Arab-Barbmares

M. Mebarki^{1*}, R. Kaidi², M. Besbaci²

¹Department of Veterinary Science, Veterinary Sciences and Agricultural Sciences Institute, University of Batna1, Algeria

²Veterinary Sciences Institute, University of Blida, Algeria

ABSTRACT: In the present study, we administered intravaginally a progesterone-releasing device (PRID) to acyclic Arab-Barb mares (n=39) in order to induce the first estrus with ovulation, for 11 days at different seasons: winter (n = 10), spring (n = 13), summer (n = 7) and autumn (n = 9). Twenty-seven of 39 mares responded to the PRID treatment with estrus and ovulation during the 42-day observation period; fewer mares were ovulated after treatment in winter (4/10, 40%), compared to those in spring (9/13, 69%), summer (7/7, 100%) and autumn (7/9, 78%) ($P < 0.05$). At Day 2 of PRID treatment, mean progesterone concentrations were significantly increased in all mares in winter ($7.20 \pm 0.49 \text{ ng mL}^{-1}$), spring ($7.30 \pm 0.64 \text{ ng mL}^{-1}$), summer ($7.5 \pm 0.58 \text{ ng mL}^{-1}$) and autumn ($7.60 \pm 0.71 \text{ ng mL}^{-1}$) ($P < 0.05$) compared to Day 1. Total concentration of progesterone [area under curve (AUC)] during the treatment period revealed the highest values ($P < 0.05$) in spring ($67.95 \pm 2.40 \text{ ng mL}^{-1} \text{ h}^{-1}$) and autumn ($65.20 \pm 1.37 \text{ ng mL}^{-1} \text{ h}^{-1}$) compared with winter ($54.19 \pm 7.00 \text{ ng mL}^{-1} \text{ h}^{-1}$) and summer ($52.23 \pm 3.32 \text{ ng mL}^{-1} \text{ h}^{-1}$). In conclusion, administration of the PRID was able to induce estrus and ovulation in mares at different seasons of the year. However, the efficacy of the treatment was not satisfactory in all seasons (low response rate in winter) and the synchrony of intervals from removal of PRID to ovulation was not effective (especially in winter).

Keywords: Mare; estrus; ovulation; PRID; progesterone.

Corresponding Author:

M. Mebarki, Department of Veterinary Science, University of Batna1, Allées 19 mai, Route de Biskra - Batna, 05000, Algeria.
E-mail address: mounir.mebarki@univ-batna.dz

Date of initial submission: 05-05-2020
Date of acceptance: 31-07-2021

INTRODUCTION

Mares are long-day seasonal breeders and start ovarian follicular activity during the spring. The ideal artificial breeding season for mares is from March to the first week of April. During this period, it is important to notice that there is a transition period characterized by delayed ovulation, and mares are not at their optimal reproductive potential (Handler et al., 2007). Moreover, mare breeders want foals born as soon as possible after the first of January (Mebarki et al., 2019), because, in the racing world, foals and yearlings are put into competition according to their year of birth. Moreover, anoestrus seasonality in the mare limits reproduction for a variable period. Mares have no sexual activity and their reproductive hormones are on basal levels during anoestrus. Thus, it is important to propose protocols for the induction of estrus during anoestrus.

A systematic reproductive manipulation of the estrous cycle using exogenous compounds such as hormonal treatments and artificial light programs are used to induce the beginning of the breeding season in mares, allowing earlier ovulation in the year (Mateu-Sánchez et al., 2016). Several protocols have been utilized for estrus induction and ovulation in mare with ovarian inactivity such as: a) GnRH and GnRH agonist (Evans and Irvine, 1977; McKinnon et al., 1997); b) oral progestagens; (Webel and Squires 1982; Wiepz et al., 1988); c) progesterone administered parenterally (Alexander and Irvine 1991); d) progesterone releasing intravaginal device (Wittkowski et al., 1982; Ataman et al., 2000); e) FSH administration (Raz et al., 2009; Niswender et al., 2004) and f) dopamine antagonists (Besognet et al., 1997; Ponzani et al., 2011). In this study, the efficacy of progesterone (progesterone intravaginal device - PRID) was investigated as a means of induction of the estrus and synchronization of ovulation in anoestrus Arab-Barb mares.

MATERIALS AND METHODS

Animals

A total of 42 non-cycling and non-lactating Arab-Barb mares coming from breeding farms in the northeast of Algeria, aged from 5 to 23 years, were included in this study. All mares spent a daily average of 8 hours on natural pastures. In addition, barley, hay or straw and a mineral vitamin complex were provided; water was freely available. Deworming was also performed at regular intervals. No artificial light pro-

gram was provided.

Treatments

Ultrasound and vaginal examinations were performed before treatment. Blood samples were also collected for determination of plasma concentrations of progesterone before each treatment; only mares with a true anoestrus (no ovarian activity and progesterone concentration $< 1 \text{ ng mL}^{-1}$) and without infectious genital problems were used in this study. A total of 42 mares received PRID, (PRID® Delta 1.55g progesterone, CEVA Santé Animale, France) for 11 days (Day 1: day of device insertion; Day 12: day of device removal). The insertion of the PRID was performed after a good washing and disinfection of the perineal region without the use of local antibiotics.

Three mares were excluded from the study (two mares lost their PRID and in one mare PRID provoked severe colics). The remaining 39 mares were divided into four groups according to the season of experimentation, 10 mares in winter, 13 in spring, 7 in summer and finally 9 in autumn. Uterus and ovaries were examined rectally before the insertion of PRID and every other day thereafter by palpation and ultrasonography (5-7.5MHz convex transducer; Mini Focus 1402, BK Medical, Denmark). The mares were checked daily since the day of PRID removal until the detection of ovulating estrus. Examination for the onset of estrus was stopped after the detection of the first ovulatory estrus. If the mares did not have an ovulatory estrus (anovulatory estrus or anoestrus) during 42 days after PRID removal, the treatment was considered as inefficient.

Blood sampling and hormone assays

Blood samples were collected daily by jugular venepuncture from Day 1 to Day 13 to determine serum progesterone concentrations. Blood samples were centrifuged immediately after collection over 10 min at 3000 g and serum was stored at $-25 \pm 6^\circ\text{C}$ until assayed. Concentrations of progesterone were measured by enzyme-linked fluorescent assay (ELFA) using automated benchtop immunoanalyzer (Vidas®, bio Mérieux, France).

Cytological examination

On the day of PRID removal, mares were examined by vaginal inspection and vaginal smears were taken by using a cytobrush to assess the inflammatory reactions of the vaginal lining. Clinical signs of vaginitis were hyperemia, increased vascularization

and a mucopurulent discharge. Mares with neutrophilic granulocytes $\geq 5\%$ among 200 cells counted on a smear, were classified as having an inflammatory reaction (vaginal inflammation).

Statistical analyses

As progesterone concentration in serum was not normally distributed, non-parametric-tests were used throughout. We investigated the relationships between estrous manifestation and progesterone concentration with Wilcoxon signed rank test for comparisons between two groups and Friedman test among more than two groups of matched data, respectively. Results were considered to be significant at $P < 0.05$. A software program SAS mixed procedure (9.2 version; SAS Institute, Inc., Cary, NC, USA) was used for all calculations, e.g. descriptive analyses (mean \pm S.E.M.), area under curve (AUC), Wilcoxon signed rank test and Friedman test. Data are represented as means \pm S.E.M.

RESULTS

Clinical data (efficacy of treatment, vaginitis and vaginal cytology)

Failure to respond to treatment was defined by failure to ovulate within 42 days of PRID removal. Failure to respond occurred in 12/39 mares. No signs of estrus were detected in 9/12 mares (6/9 mares in winter, 1/9 mare in spring and 2/9 mares in autumn). In spring season, 3/12 mares manifested just one anovulatory estrus followed by a prolonged anestrus again. Twenty-seven mares responded to the PRID treatment with ovulating estrus. Significantly fewer anestrous mares ovulated after treatment in winter (4/10, 40%) when compared to mares in spring (9/13, 69%), summer (7/7, 100%) and autumn (7/9, 78%) ($P < 0.05$). Furthermore, intervals from removal of PRID to successive estrus did not differ among treatment groups (winter: 3.9 ± 0.4 days, spring: 3.7 ± 0.2 days, summer: 3.2 ± 0.2 days and autumn: 3.4 ± 0.5 days). Intervals from PRID removal to successive ovulations were longer in winter (19.75 ± 3.41 days; min: 14, max: 23), followed by spring (13.75 ± 5.42 days; min: 5, max: 22), autumn (12.25 ± 5.97 days; min: 5, max: 21) and summer (9 ± 3.74 days; min: 5, max: 14; $P < 0.05$). Comparison of ovulating follicle diameters after PRID treatment revealed no significant difference between seasons (winter: 4.25 ± 0.30 cm, spring: 4.34 ± 0.25 cm, summer: 3.91 ± 0.23 cm and autumn: 4.14 ± 0.55 cm).

All mares presented moderate vaginitis at PRID removal. Furthermore, the cytological examination showed a percentage of neutrophilic granulocytes greater than 5% (Fig. 1) in all mares, which can be classified as vaginal inflammation.




Figure 1. Inflammatory vaginal smear rich in neutrophils

Progesterone concentrations

Serum progesterone concentrations at PRID insertion (Day 1) were less than 1.2 ng mL^{-1} in all mares. At Day 2 of PRID treatment, mean progesterone concentrations were significantly increased in all mares in winter, spring, summer and autumn, (7.20 ± 0.49 , 7.30 ± 0.64 , 7.5 ± 0.58 and $7.60 \pm 0.71 \text{ ng mL}^{-1}$; $P < 0.05$; Fig. 2). Then, mean progesterone concentrations decreased steadily until removal of PRID, whereas all mares showed concentrations below 1 ng mL^{-1} at Day 13 (winter 0.22 ± 0.01 ; spring 0.28 ± 0.01 ; summer 0.27 ± 0.00 and autumn $0.47 \pm 0.08 \text{ ng mL}^{-1}$; $P > 0.05$). Total concentration of progesterone (AUC) during the treatment period (Fig. 3) revealed the highest values in spring ($67.95 \pm 2.40 \text{ ng mL}^{-1} \text{ h}^{-1}$) and autumn ($65.20 \pm 1.37 \text{ ng mL}^{-1} \text{ h}^{-1}$) compared to winter ($54.19 \pm 7.00 \text{ ng mL}^{-1} \text{ h}^{-1}$) and summer ($52.23 \pm 3.32 \text{ ng mL}^{-1} \text{ h}^{-1}$; $P < 0.05$).




Figure 2. Daily serum progesterone concentrations in mares during PRID treatments at different seasons




Figure 3. Total serum progesterone concentrations in mares during PRID treatments. Significant differences ($P < 0.05$) among seasons are marked by different superscripts (a and b)

DISCUSSION

In this study, the efficacy of PRID for estrous induction revealed acceptable results in anestrous mares. The manual placement of the devices in the vagina was easy to perform in this study as previously reported by Grimmett et al. (2002). Furthermore, the mares at pasture received the correct amount of drug every day, as it is demonstrated by plasma progesterone concentrations during PRID treatment.

A low rate of devices was lost. It is estimated that about 4% of mares expelled the coil, and the most PRIDs remained in place during the entire treatment period. PRID was originally developed for use in cattle (Broadbent et al., 1993; Uehlinger et al., 1995; Vanderwall et al., 2007). In cows, loss rates of 10 and 12% (Andresen et al., 1982; Newcombe, 2002) have been described. Among mares' losses rang from no losses (Arbeiter et al., 1994; Handler et al., 1999) for up to 5% (Taylor et al., 1982).

Although, most mares showed mild discomfort, 2.56% showed severe pain. The insertion of vaginal devices causes moderate vaginitis with clinical signs such as hyperemia and mucopurulent vaginal

discharge, which disappeared within two to three days after the coil removal. However, the data from our study showed no signs of clinical endometritis or ascending cervicitis after PRID insertion without antibiotics. Local application of antibiotics to PRID insertion was recommended to reduce the incidence and severity of vaginitis (Rutten et al., 1986). Vaginal mucosa irritation (Arbeiter et al., 1994) and bacterial contamination by faeces and skin (Bulman et al., 1978) were supposed to contribute to the emergence of vaginitis caused by the intravaginal devices.

Treatment with the intra-vaginal device PRID for estrus induction revealed acceptable results in anestrous mares. Ovulation occurred in more than 69% of mares (except winter - 40%) which is similar to the results of Handler et al. (2006), who reported that more than half of the mares showed successful results of synchronization after PRID treatment. However, Alexander and Irvine (1991) reported that the ovulation rate had decreased to 37.5% in treated mares, which are consistent with the results of other studies (Evans and Irvine, 1979; Palmer, 1979; Turner et al., 1981; Alexander and Irvine, 1991). Contrarily, Squires et al. (1999) concluded that the efficacy of PRID treatment for synchronization of ovulation was poor as demonstrated by low rates of suitably synchronized mares in all seasons.

In contrast, according to our data, the efficacy of the treatment was not satisfactory concerning ovulation synchronization, because intervals from PRID removal to ovulation varied within a wide range in all mares, especially those treated in winter. This may be due to the fact that the mares are in true period of seasonal anestrus (short days). During this period GnRH (Hart et al., 1984) and LH (Hart et al., 1984; Thompson et al., 1986) are much lower regardless of the lack of progesterone. Similar observations were previously reported by Göhring et al. (1999). Handler et al. (2007) consider that their results are unsatisfactory in terms of the use of PRID for synchronization of mares during embryo transfer programs.

Our results share a number of similarities with Newcombe (2002) findings where the efficacy of PRID for estrus synchronization revealed acceptable results. However, Handler et al. (2007) reported low accuracy in ovulation synchronization. Newcombe and Wilson (1997) suggested the use of human chorionic-gonadotropin (hCG) for hastening ovulations during induced estrus. Arbeiter et al. (1994) obtained much better response after administration of extend-

ed-acting GnRH agonists.

In conclusion, administration of the intravaginal device releasing progesterone (PRID) was able to induce estrus and ovulation in mares indifferent seasons of the year. However, unlike the situation in cows, the efficacy of the treatment was not satisfactory in all seasons (low response rate in winter) and synchronization of ovulation was not effective (in all seasons and especially in winter) in mares.

ACKNOWLEDGMENTS

The authors are grateful for all the help and co-operation provided by the many participating horse owners in the region of Remila (Algeria). The assistance of, Lamine Noui and Nadjib Ghassir in data collection is greatly appreciated.

CONFLICT OF INTEREST

There is no reported conflict of interest.

REFERENCES

Alexander SL, Irvine CHG (1991) Control of onset of breeding season and its artificial regulation by progesterone treatment. *J Reprod Fertil Suppl* 44:307-318.

Andresen P, Schulte B, Grunert E, Andresen U (1982) Experiences with Abbovestrol 1 used for cycle synchronization in heifers. *Dtsch Tierärztl Wschr* 89:241-4.

Arbeiter K, Barth U, Jöchle W (1994) Observations on the use of progesterone intravaginally and of deslorelin STI in acyclic mares for induction of ovulation. *J Equine Vet Sci* 14:21-25.

Ataman MB, Günay A, Günay U, Baran A, Uzman M (2000) Oestrous synchronization with progesterone impregnated device and prostaglandin F2a both combined with human chorionic gonadotropin in transitional mares. *Revue Med Vet* 151:1031-4.

Besognet B, Hansen BS, Daels PF (1997) Induction of reproductive function in anestrous mares using a dopamine antagonist. *Theriogenology* 47:467- 80.

Broadbent PJ, Tregaskes LD, Dolman DF, Franklin MF, Jones RL (1993) Synchronization of estrus in embryo transfer recipients after using a combination of PRID or CIDR-B plus PGF2. *Theriogenology* 39: 1055-1065.

Bulman DC, McKibbin PE, Appleyard WT, Lamming GE (1978) Effect of a progesterone-releasing intravaginal device on the milk progesterone levels, vaginal flora, milk yield and fertility of cyclic and non-cyclic dairy cows. *J Reprod Fert* 53:289-296.

Evans MJ, Irvine CH (1977) Induction of follicular development, maturation and ovulation by gonadotropin releasing hormone administration to acyclic mares. *Biol Reprod.* 16:452- 62.

Evans MJ, Irvine CHG (1979) Induction of follicular development and ovulation in seasonally acyclic mares using gonadotrophin-releasing hormone and progesterone. *J Reprod Fert Suppl* 27: 113-121.

Göhring C, Aurich C, Lange J, Hoppen H-O, Aurich JE (1999) Therapeutic and prophylactic effect of LH-release in cattle. *Tierärztl Prax G* 27: 25-9.

Grimmett JB, Hanlon DW, Duirs GF, Jochle W (2002) A new intra-vaginal progesterone-releasing device (CueMareTM) for controlling the estrous cycle in mares. *Theriogenology* 58: 585-587.

Handler J, Arbeiter K, Jöchle W (1999) Stimulation of fertile ovulations in mares during the transition period using an intravaginal progesterone device (CIDR-BTM) and subsequently deslorelin acetate (OvuplantTM). *Reprod Domest Anim* 34: 24.

Handler J, Schönlieb S, Hoppen H, Aurich C (2007) Influence of reproductive stage at PRIDTM insertion on synchronization of estrus and ovulation in mares. *Anim Reprod Sci* 97: 382-393.

Handler J, Schönlieb S, Hoppen HO, Aurich C (2006) Seasonal effects on attempts to synchronize estrus and ovulation by intravaginal application of progesterone-releasing device (PRIDTM) in ponds. *Theriogenology* 65: 1145-1158.

Hart PJ, Squires EL, Imel KJ, Nett TM (1984) Seasonal variation in hypothalamic content of gonadotropin-releasing hormone (GnRH), pituitary receptors for GnRH and pituitary content of luteinizing hormone and follicle stimulating hormone in the mare. *Biol. Reprod.* 30:1055-1062.

Mateu-Sánchez S, Newcombe JR., Garcés-Narro C, Cuervo-Ango J (2016) The period of the follicular phase during which the uterus of mares shows estrus-like echotexture influences the subsequent pregnancy rate. *Theriogenology* 86 (6): 1506-1515.

McKinnon AO, Vasey JR, Lescun TB, Trigg TE (1997) Repeated use of a GnRH analogue deslorelin (Ovuplant) for hastening ovulation in the transitional mare. *Equine Vet J.* 29:153-5.

Mebarki M, Kaidi R, Azizi A, Basbaci M (2019) Comparative efficacy of two-dimensional mode and color Doppler sonography in predicting gender of the equine fetus. *Veterinary World* 12 (2): 325-330.

Newcombe JR, Wilson MC (1997) The use of progesterone releasing intra-vaginal devices to induce estrus and ovulation in anestrous Standard-bred mares in Australia. *Pract Equine* 19: 13-21.

Newcombe JR (2002) Field observation on the use of a progesterone-releasing intravaginal device to induce estrus and ovulation in seasonally anestrous mares. *J Equine Vet Sci* 22: 378-382.

Niswender KD, McCue PM, Squires EL (2004) Effect of purified equine follicle-stimulating hormone on follicular development and ovulation in transitional mares. *J Equine Vet Sci*. 24: 37-9.

Palmer E (1979) Reproductive management of mares without detection of oestrus. *J Reprod Fertil Suppl* 27: 263-270.

Panzani D, Zicchino I, Taras A, Marmorini P, Crisci A, Rota A, Camillo F (2011) Clinical use of dopamine antagonist sulpiride to advance first ovulation in transitional mares. *Theriogenology*. 75:138-43.

Raz T, Carley S, Card C (2009) Comparison of the effects of eFSH and deslorelin treatment regimens on ovarian stimulation and embryo production of donor mares in early vernal transition. *Theriogenology*. 71:1358-66.

Rutten DR, Chaffaux S, Valon M, Deletang F, De Haas V (1986) Progesterone therapy in mares with abnormal oestrous cycles *Vet Rec*. 119: 569-571.

Squires EL, McCue PM, Vanderwall D (1999) The current status of equine embryo transfer. *Theriogenology* 59: 151-170.

Taylor TB, Pemstein R., Loy RG (1982) Control of ovulation in mares in the early breeding season with ovarian steroids and prostaglandin. *J Reprod Fert Suppl* 32:219-224.

Thompson DL, Johnson L, George RL, Garza F (1986) Concentrations of prolactin, luteinizing hormone and follicle stimulating hormone in pituitary and serum of horses: effect of sex, season and reproductive state. *J. Anim. Sci.* 63: 854-860.

Turner DD, Garcia MC, Weibel SK, Ginther OJ (1981) Influence of follicular size on the response of mares to allyl trenbolone given before the onset of the ovulatory season. *Theriogenology* 16: 73-84.

Uehlinger H, Binder H, Hauser B, Rusch P, Zerobin K (1995) Comparison by hormone analysis of the intravaginal devices CIDRTM and PRID® in ovariectomised cows. *Schweiz Arch Tierheilk* 137: 81-86.

Vanderwall DK, Marquardt JL, Woods GL (2007) Use of a compounded long-acting progesterone formulation for equine pregnancy maintenance. *J Equine Vet Sci* 27: 62-66.

Weibel SK, Squires EL (1982) Control of the oestrous cycle in mares with altrenogest. *J Reprod Fertil Suppl*. 32:193- 8.

Wiepz GJ, Squires EL, Chapman PL (1988) Effects of norgestomet, altrenogest, and/or estradiol on follicular and hormonal characteristics of late transitional mares. *Theriogenology* 30: 181-93.

Wittkowski G, Grunert E, Bukowski A (1982) Heat induction by a progesterone releasing intravaginal device (Abbovestrol1). *Dtsch Tierärztl Wschr*. 89:244-7.